Paper39100682
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.
Majumder B and 3 others. Front Immunol, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms. Papers, record 39100682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39100682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| DNA Mismatch Repair | Major topic |
| Humans | |
| Precision Medicine | |
| Animals | |
| Colorectal Neoplasms | |
| Signal Transduction |
Source PubMed
References235
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38495713 | Assessing cell viability with dynamic optical coherence microscopy. | Biomed Opt Express | 2024 | https://conductscience.org/library/papers/38495713 | PubMed |
| 2 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 3 | 34581895 | Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. | Med Oncol | 2021 | https://conductscience.org/library/papers/34581895 | PubMed |
| 4 | 19909745 | Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. | Gastroenterology | 2010 | https://conductscience.org/library/papers/19909745 | PubMed |
| 5 | 34343496 | CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. | Cell | 2021 | https://conductscience.org/library/papers/34343496 | PubMed |
| 6 | 33828294 | Evaluating eligibility criteria of oncology trials using real-world data and AI. | Nature | 2021 | https://conductscience.org/library/papers/33828294 | PubMed |
| 7 | 35687697 | ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. | Sci Immunol | 2022 | https://conductscience.org/library/papers/35687697 | PubMed |
| 8 | 35508177 | Patient-derived micro-organospheres enable clinical precision oncology. | Cell Stem Cell | 2022 | https://conductscience.org/library/papers/35508177 | PubMed |
| 9 | 31730395 | The Acidic Tumor Microenvironment as a Driver of Cancer. | Annu Rev Physiol | 2020 | https://conductscience.org/library/papers/31730395 | PubMed |
| 10 | 36509911 | Rational combinations of targeted cancer therapies: background, advances and challenges. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/36509911 | PubMed |
| 11 | 32451418 | TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer. | Nat Commun | 2020 | https://conductscience.org/library/papers/32451418 | PubMed |
| 12 | 35145327 | Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. | Nat Cancer | 2022 | https://conductscience.org/library/papers/35145327 | PubMed |
| 13 | 25554788 | Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. | Science | 2015 | https://conductscience.org/library/papers/25554788 | PubMed |
| 14 | 35247870 | Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application. | ESMO Open | 2022 | https://conductscience.org/library/papers/35247870 | PubMed |
| 15 | 33554860 | shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. | Elife | 2021 | https://conductscience.org/library/papers/33554860 | PubMed |
| 16 | 38266104 | The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. | Sci Transl Med | 2024 | https://conductscience.org/library/papers/38266104 | PubMed |
| 17 | 36596344 | Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type. | Hum Pathol | 2023 | https://conductscience.org/library/papers/36596344 | PubMed |
| 18 | 38039966 | Intestinal microbiota-specific Th17 cells possess regulatory properties and suppress effector T cells via c-MAF and IL-10. | Immunity | 2023 | https://conductscience.org/library/papers/38039966 | PubMed |
| 19 | 33051339 | Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/33051339 | PubMed |
| 20 | 37074042 | BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth. | Cancer Res | 2023 | https://conductscience.org/library/papers/37074042 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42781243 | Targeting the DNA Damage Response in Cancer. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42781243 | PubMed |
| 42596654 | cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy. | Cancer Biol Med | 2026 | https://conductscience.org/library/papers/42596654 | PubMed |
| 42459668 | Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects. | Front Immunol | 2026 | https://conductscience.org/library/papers/42459668 | PubMed |
| 42369139 | Relationship between MLH1, MSH2, MSH6, and PMS2 protein expression status and clinicopathological characteristics in colorectal cancer tissues. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42369139 | PubMed |
| 41583489 | Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation. | Front Immunol | 2025 | https://conductscience.org/library/papers/41583489 | PubMed |
| 41080580 | Metformin-associated gut microbiota remodeling correlates with reinvigorated splenic immunity in aged mice: microbiome-immune crosstalk via the gut-spleen axis. | Front Immunol | 2025 | https://conductscience.org/library/papers/41080580 | PubMed |
| 40453103 | Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances. | J Liq Biopsy | 2025 | https://conductscience.org/library/papers/40453103 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39100682
GET https://conductscience.org/api/papers/v1/39100682/references?page=2